- Conditions
- Colon Cancer
- Interventions
- FOLFOX and bevacizumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 723
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, ursodiol, RNA analysis, gene expression analysis, polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, positron emission tomography (PET)
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Small Bowel Adenocarcinoma
- Interventions
- Nanoliposomal irinotecan, Oxaliplatin, 5 fluorouracil, Leucovorin
- Drug
- Lead sponsor
- Tiago Biachi de Castria
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Chicago, Illinois • Fort Wayne, Indiana + 4 more
- Conditions
- Colorectal Cancer, Pancreatic Cancer
- Interventions
- BMS-813160, Nivolumab, Nab-paclitaxel, Gemcitabine, 5-fluorouracil (5-FU), Leucovorin, Irinotecan
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 21 more
- Conditions
- Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic, Gastric Cancer
- Interventions
- Bemarituzumab, Modified FOLFOX6
- Biological · Drug
- Lead sponsor
- Five Prime Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Greenbrae, California • Whittier, California + 4 more
- Conditions
- Advanced Solid Tumors, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
- Interventions
- BKM120, mFOLFOX6
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Head and Neck Cancer
- Interventions
- cetuximab, cisplatin, docetaxel, fluorouracil, computed tomography, positron emission tomography, quality-of-life assessment, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Gastrointestinal Diseases
- Interventions
- 5-Fluorouracil, Docetaxel, Oxaliplatin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
- Interventions
- oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 9
- States / cities
- Fairfield, Connecticut • Guilford, Connecticut • Hartford, Connecticut + 6 more
- Conditions
- Neoplasms
- Interventions
- feladilimab (GSK3359609), GSK3174998, Pembrolizumab, Docetaxel, Pemetrexed, Paclitaxel plus Carboplatin, Gemcitabine plus Carboplatin, Fluorouracil (5-FU) plus carboplatin or cisplatin, Dostarlimab, Cobolimab, Bintrafusp alfa
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 93 Years
- Enrollment
- 829 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 9
- States / cities
- Duarte, California • Los Angeles, California • Sarasota, Florida + 4 more
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- Paclitaxel, NALIRIFOX
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Colorectal Neoplasms
- Interventions
- 5-fluorouracil, bevacizumab, capecitabine, irinotecan, folinic acid, oxaliplatin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 45
- States / cities
- Mobile, Alabama • Long Beach, California • Los Angeles, California + 41 more
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- aflibercept, oxaliplatin, leucovorin, fluorouracil, Correlative Studies, DCE MRI, f18FDG-PET, PET (positron emission tomography)
- Biological · Drug · Other + 2 more
- Lead sponsor
- John Hays
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 6
- States / cities
- Ann Arbor, Michigan • Buffalo, New York • The Bronx, New York + 3 more
- Conditions
- Pancreatic Cancer
- Interventions
- DC Vaccine + Standard of Care Chemotherapy
- Biological
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Stage II Rectal Cancer, Stage III Rectal Cancer
- Interventions
- Capecitabine, 5-FU, Leucovorin, Oxaliplatin, radiation, total mesorectal excision
- Drug · Radiation · Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- zolbetuximab, placebo, oxaliplatin, folinic acid, fluorouracil
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 565 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 42 more
- Conditions
- Breast Cancer
- Interventions
- 5-Fluorouracil, Cyclophosphamide, Doxorubicin, Paclitaxel, Epirubicin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Actinic Keratosis
- Interventions
- Biopsy, Calcipotriene, Fluorouracil
- Procedure · Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Boston, Massachusetts • St Louis, Missouri + 1 more
- Conditions
- Metastatic Colorectal Cancer, Adjuvant Colorectal Cancer, 5-FU Containing Therapy Regimens
- Interventions
- Not listed
- Lead sponsor
- Saladax Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- La Jolla, California • Skokie, Illinois • Las Vegas, Nevada + 2 more
- Conditions
- Head and Neck Cancer
- Interventions
- fluorouracil, gemcitabine hydrochloride, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8
- Interventions
- Biopsy of Bladder, Biospecimen Collection, Cisplatin, Computed Tomography, Cystoscopy, Durvalumab, Fluorouracil, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Mitomycin, Patient Observation, Radiation Therapy
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 216
- States / cities
- Anchorage, Alaska • Fort Smith, Arkansas • Hot Springs, Arkansas + 153 more
- Conditions
- Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
- Interventions
- Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Patritumab Deruxtecan
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more
- Conditions
- Resectable Pancreatic Cancer
- Interventions
- Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable, -Oxaliplatin 85 mg/m2 IV on Day 1, -Irinotecan 180 mg/m2 IV on Day 1, -5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours
- Other · Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Actinic Keratoses
- Interventions
- 5% 5-fluorouracil (5-FU) powder, 5% 5-fluorouracil (5-FU) powder PLUS 15% Aluminum Chloride Hexahydrate (ACH)
- Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia